



4-26-03
16PH

1634

PATENT
ATTORNEY DOCKET NO. 03848-00093

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Janet A. Warrington et al.

Serial No.: 09/950,016

Filed: September 10, 2001

Title: METHODS FOR DETECTING AND
DIAGNOSING ORAL CANCER

)
)
) Examiner:
)
) Diana B. Johannsen
)
) Art Unit: 1634
)
)
)

Commissioner for Patents
BOX Non-Fee Amendment
Washington, D.C. 20231

TRANSMITTAL LETTER

Sir:

In regard to the above identified application, we are transmitting herewith the attached:

1. Response to Restriction Requirement, and
2. Return postcard.

No fees are believed due. The Commissioner is hereby authorized to charge any additional fees to Deposit Account No. 19-0733.

Respectfully submitted,

Dated:

April 25, 2003

By

John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
(617) 720-9600



PATENT
ATTORNEY DOCKET NO. 03848-00093

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:)
)
Janet A. Warrington et al.) Examiner:
)
Serial No.: 09/950,016) Diana B. Johannsen
)
Filed: September 10, 2001) Art Unit: 1634
)
Title: METHODS FOR DETECTING AND)
DIAGNOSING ORAL CANCER)

Commissioner for Patents
BOX Non-Fee Amendment
Washington, D.C. 20231

RESPONSE TO RESTRICTION REQUIREMENT

Dear Sir:

This is in response to the office action mailed March 25, 2003. Kindly consider the following remarks in the above-referenced application.


REMARKS

At page 2 of the instant Office Action, the Examiner has required restriction among six groups of inventions, namely claims 1-2, 7-14 and 18-25, drawn to methods of diagnosing cancer by detecting nucleic acids (Group I), classified in class 435, subclass 6; claims 3-6, drawn to methods of classifying and differentiating cell types (Group II), classified in class 435, subclass 6; claims 7-17 and 22-25, drawn to methods of diagnosing cancer by detecting proteins (Group III), classified in class 435, subclass 7.1; claims 26-28 and 30-34, drawn to methods of assessing the efficacy of a compound *in vitro* (Group IV), classified in class 435, subclasses 6 and 7.1; claim 29, drawn to methods of assessing the efficacy of a therapy *in vivo* (Group V), classified in class 424, subclass 9.2 and class 435, subclasses 6 and 7.1; and claims 35-36, drawn to kits comprising nucleic acid probes (Group VI), classified in class 536, subclass 24.31.

Applicants elect the invention of Group I, claims 1-2, 7-14 and 18-25 without traverse for prosecution on the merits.

Respectfully submitted,

Dated: April 25, 2003



John P. Iwanicki, Reg. No. 34,628
BANNER & WITCOFF, LTD.
28 State Street, 28th Floor
Boston, MA 02109
(617) 720-9600